Technical Data
Anti-Nuclear Antibodies, Mouse (ANA) BioAssay™ ELISA Kit
Kits and Assays Storage: 4°CShipping: Blue Ice
Principle of the Test:
Anti-Nuclear Antibodies (ANA) ELISA kit is based on binding of mouse ANA IgG+IgA+IgM from serum samples to extracted nuclear antigen immobilized on microtiter wells. After a washing step, IgG (HRP) goat anti-mouse is added. After another washing step, to remove all the unbound enzyme conjugate, chromogenic substrate (TMB) is added and color developed. The enzymatic reaction (blue color) is directly proportional to the amount of ANA present in the sample. The reaction is terminated by adding stopping solution (converts blue to yellow). Absorbance is then measured on a microtiter well ELISA reader at 450nm. The activity of total mouse antibodies in samples is calculated relative to mouse ANA calibrators.

Kit Components:
A2298-12J1: Microtiter Strip, 1x96 wells
A2298-12J2: Standard 50U/ml, 1x650ul
A2298-12J3: Standard 200U/ml, 1x650ul
A2298-12J4: Standard 500U/ml, 1x650ul
A2298-12J5: Standard 1000U/ml, 1x650ul
A2298-12J8: IgG (HRP) 100X, 1x150ul
A2298-12J9: Sample Diluent 20X, 1x10ml
A2298-12J10: Wash Solution 100X, 1x10ml
A2298-12J11: TMB Substrate, 1x12ml
A2298-12J12: Stop Solution (1% H2SO4), 1x12ml
A2298-12J13: Low NSB Sample Diluent 1x30ml

Storage and Stability:
Store all components at 4°C. Stable for 6 months. For maximum recovery of product, centrifuge the original vial prior to removing the cap.
Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
US Biological Application Reference: 1. Mangsbo, S.M., et al., J. Immunother. 33: 225-235 (2010). General References: 1. Sakic, B., Biol. Psychiatry 57: 679-687 (2005). 2. Sakic, B., J. Neuroimmunol. 169: 68-85 (2005). 3. Zhang, J.Q., J. Exp. Med. 200: 1467-1478 (2005). 4. Pfau, J.C., Toxicology 195: 167-176 (2004). 5. Blossom, S.J., J. Autoimmunity 23: 211-220 (2004). 6. Lauder, A.J., J. Immunol. 173: 113-122 (2004). 7. Ballok, D.A., Behavioural Brain Res. 140: S1-2, 119-130 (2003). 8. Dobrovolsky, V.N., Molecular Genetics Metabol. 78: 1-10 (2003). 9. Ballok, D.A., Brain Res. 964: 200-210 (2003). 10. Brown, J.M., Clin. Exp. Immunol. 131(3): 415 (2003). 11. Malek, T.R., Immunity 17: 167-178 (2002). 12. Sakic, B., J. Neuroimmunol. 129: 84-96 (2002). 13. Khan, M.F., Toxicol. Appl. Pharmacol. 170(2): 88-92 (2001). 14. Marica, D., Brain Res. 920: 183-193 (2001). 15. Sakic, B., J. Neuroimmunol. 111: 93-101 (2000). 16. Khan, M.F., Immunopharmacol. Immunotoxicol. 19(2): 265-277 (1997). 17. Khan, M.F., Toxicol. Appl. Pharmacol. 134: 155-160 (1995).

Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.